The content on this site is intended for healthcare professionals only
Dr Shubassi provides a robust overview of CDKs 4 and 6 as part of the 'Coming of Age for CDK 4/6 Inhibitors' symposium at ESMO 2016.
Supported by a grant from Pfizer Inc.
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
Guiding transplant decisions in multiple myeloma with MRD
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC
ESMO 2024: Latest in EGFR mutated NSCLC
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
The current status of multiple myeloma diagnosis and treatment
Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC
